Abstract: Provided is a fusion protein, which comprises human fibroblast growth factor 21 and glucagon-like-peptide-1 or its analogs. Also provided is the medicament composition comprising the fusion protein, which can be used for treating or preventing obesity, diabetes, hyperglycemia and hyperlipidemia etc.
Type:
Grant
Filed:
March 12, 2010
Date of Patent:
August 19, 2014
Assignee:
Chongqing Fagen Biomedical Inc.
Inventors:
Kai Fan, Zhiquan Zhao, Chun Zhang, Yong Chen, Hua Luo, Li Yang, Honghong Liu
Abstract: Provided are a PEGylated analogue protein of canine urate oxidase, preparation method and use thereof. The analogue protein of canine urate oxidase is a canine urate oxidase, or a chimeric protein comprising part of the amino acid sequence of a canine urate oxidase and part of the amino acid sequence of a human urate oxidase, or a mutant protein thereof. The PEGylated analogue protein of canine urate oxidase and pharmaceutical compositions thereof according to the present invention can be used for the prevention and/or treatment of hyperuricemia and chronic gout.
Type:
Application
Filed:
February 14, 2012
Publication date:
March 6, 2014
Applicant:
Chongqing Fagen Biomedical Inc. No. 80 4th Street Keyuan
Inventors:
Chun Zhang, Kai Fan, Xuefeng Ma, Li Yang, Chunlan Hu, Hua Luo, Xiang Mei
Abstract: Disclosed is a recombinant human insulin or analog conjugate thereof. Said conjugate is formed by connecting the ?-amino group of lysine 29 of the B chain to activated polyethylene glycol by means of an amide bond. Further disclosed is a method of preparing said conjugate, a pharmaceutical compound, and a use for said conjugate in preparing medication for treating Type 1 and Type 2 diabetes.
Type:
Application
Filed:
March 19, 2012
Publication date:
February 27, 2014
Applicant:
Chongqing Fagen Biomedical Inc.
Inventors:
Kai Fan, Yu Cao, Yong Chen, Hongliang Li, Hairong Chen, Ying Wan
Abstract: The present invention provides a humanized recombinant uricase and mutants thereof, wherein the humanized recombinant uricase is a chimeric protein which comprises amino acids of non-human mammal uricase and amino acids of human uricase. The humanized recombinant unease and mutants thereof have reduced immunogenicity in human, and can be used for the treatment of hyperuricemia and gout.
Type:
Grant
Filed:
March 12, 2010
Date of Patent:
November 19, 2013
Assignee:
Chongqing Fagen Biomedical Inc.
Inventors:
Kai Fan, Chun Zhang, Xuefeng Ma, Xiang Mei, Chunlan Hu
Abstract: Provided is a homodimer of insulinotropic peptide analogues and method for preparation thereof and use thereof, wherein the insulinotropic peptide analogue comprises GLP-1 and Exendin-4. The homodimer of insulinotropic peptide analogues of the invention is made by conjugating two identical insulinotropic peptide analogue molecules at the C-terminal Cys residues via disulfide bond or PEG molecule. The homodimer of insulinotropic peptide analogues of the invention has superior stability and biological activity in vivo, and prolonged half-life in the circulation, and can be used for the preparation of hypoglycemic drugs.
Type:
Grant
Filed:
March 15, 2010
Date of Patent:
October 15, 2013
Assignee:
Chongqing Fagen Biomedical Inc.
Inventors:
Kai Fan, Zhiquan Zhao, Yong Chen, Chun Zhang, Lin Wang
Abstract: Provided is a homodimer of insulinotropic peptide analogues and method for preparation thereof and use thereof, wherein the insulinotropic peptide analogue comprises GLP-1 and Exendin-4. The homodimer of insulinotropic peptide analogues of the invention is made by conjugating two identical insulinotropic peptide analogue molecules at the C-terminal Cys residues via disulfide bond or PEG molecule. The homodimer of insulinotropic peptide analogues of the invention has superior stability and biological activity in vivo, and prolonged half-life in the circulation, and can be used for the preparation of hypoglycemic drugs.
Type:
Application
Filed:
March 15, 2010
Publication date:
November 1, 2012
Applicant:
CHONGQING FAGEN BIOMEDICAL INC.
Inventors:
Kai Fan, Zhiquan Zhao, Yong Chen, Chun Zhang, Lin Wang
Abstract: Provided is a fusion protein, which comprises human fibroblast growth factor 21 and glucagon-like-peptide-1 or its analogs. Also provided is the medicament composition comprising the fusion protein, which can be used for treating or preventing obesity, diabetes, hyperglycemia and hyperlipidemia etc.
Type:
Application
Filed:
March 12, 2010
Publication date:
September 20, 2012
Applicant:
Chongqing Fagen Biomedical Inc.
Inventors:
Kai Fan, Zhiquan Zhao, Chun Zhang, Yong Chen, Hua Luo, Li Yang, Honghong Liu